Clinical Trials Logo

Tremor clinical trials

View clinical trials related to Tremor.

Filter by:

NCT ID: NCT02207946 Completed - Clinical trials for Essential Tremor of the Upper Limbs

Botulinum Toxin A to Treat Arm Tremor

Start date: December 5, 2014
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.

NCT ID: NCT02197104 Completed - Clinical trials for Fragile X Tremor/Ataxia Syndrome

Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome

Start date: January 2015
Phase: Phase 2
Study type: Interventional

The objective of this study is to determine if citocoline is effective for balance abnormalities and to stabilize cognitive decline in patients with fragile X-associated tremor ataxia syndrome. The study will test 1000mg twice daily of citocoline for 12 months in an open label pilot study, with study visits at baseline, 3, 6, and 12 months.

NCT ID: NCT02132052 Completed - Parkinson Disease Clinical Trials

Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.

PHENO
Start date: November 2013
Phase:
Study type: Observational

Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.

NCT ID: NCT02111369 Completed - Essential Tremor Clinical Trials

Propranolol and Botulinum Toxin for Essential Vocal Tremor

Start date: May 2014
Phase: Phase 4
Study type: Interventional

Essential tremor is the most common adult-onset movement disorder, and essential voice tremor is the vocal manifestation of essential tremor. While nearly all essential tremor patients experience hand tremor, many also manifest head tremor and voice tremor. Essential voice tremor can lead to increased vocal effort, decreased intelligibility, and misconstrued emotional state. Only one medication, propranolol, is FDA-approved to treat essential tremor. Propranolol is not felt to be nearly as effective for axial tremors (head, trunk, neck) as it is for extremity tremors. However, this has not been studied with any objective assessment in a prospective way for EVT. For patients with essential voice tremor, the limited published data suggests that botulinum toxin has been shown to lead to functional voice improvement. Botulinum toxin, though also not well-studied with objective voice outcomes, is a commonly used clinical therapy for treatment of essential voice tremor. While it is used more often for essential voice tremor than propranolol therapy, botulinum toxin also has not been prospectively studied with validated, objective voice outcome measures. The investigators would like to determine if propranolol has any significant effect on vocal tremor. The investigators would also like to determine, in an objective way, the effect of botulinum toxin on vocal tremor. If effective, propranolol would provide an affordable and non-invasive alternative or addition to botulinum toxin injections for patients with essential voice tremor.

NCT ID: NCT02095600 Completed - Clinical trials for Severe Upper Limb Tremor Refractory to Medical Therapy

Radiosurgery for Drug Resistant Invalidating Tremor

DB-SRS
Start date: April 2011
Phase: N/A
Study type: Interventional

Stereotactic lesioning of thalamus and basal ganglia for treatment of tremor is a well-known procedure which, prior to the introduction of deep brain stimulation, or DBS, was usually achieved using stereotactic surgical procedures. Radiosurgery of invisible targets to treat movement disorders and intractable pain are still the domain of frame-based procedures, due to the need of a solid reference system registered to the anterior commissure-posterior commissure (AC-PC) line, which allows the use of stereotactic atlases. In this study we want to utilize a mathematical method that uses atlas-derived stereotactic coordinates to perform frameless images-guided radiosurgery of such functional targets Particularly the aim of the present study is to investigate both the efficacy and the safety of the methodology to treat upper limb and hand tremor in elderly or in patients which are not ot susceptible of surgical procedures. For these reasons a dose escalation prospective trial have been designed.

NCT ID: NCT02087046 Completed - Essential Tremor Clinical Trials

Deep Brain Stimulation (DBS) for the Suppression of Tremor

Start date: October 2005
Phase: N/A
Study type: Interventional

The purpose of the proposed study is to demonstrate the safety and efficacy of the ANS Totally Implantable Deep Brain Stimulation System in the VIM nucleus of the thalamus implanted for the treatment of tremor due to essential tremor. This study will be included in the Pre-Market Approval Application to support the safety of this device in use.

NCT ID: NCT02071446 Completed - Parkinson's Disease Clinical Trials

Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes

LFP DBS
Start date: March 2014
Phase: N/A
Study type: Observational

Deep Brain Stimulation (DBS) is an FDA approved, and widely used method for treating the motor symptoms of Parkinson's Disease (PD), Essential Tremor (ET) and Dystonia. Over 100,000 patients worldwide have now been implanted with DBS devices. The DBS target regions in the brain are the Subthalamic nucleus (STN), the Internal Segment of Globus Pallidus (GPi), or the Ventral Intermediate Nucleus of the Thalamus (VIM). In order to place the DBS electrode in the target location, a combination of two 3D imaging techniques; 3D MRI and CT, are used. Data are also collected from individual nerve cells to help find the best location for the DBS electrode in each patient. This electrode recording takes place during the standard surgical implantation of the DBS electrode, and is part of the standard clinical technique. The investigators plan to collect additional data from populations of neurons during the DBS surgery in an effort to further improve the placement of the DBS electrode. These "Local Field Potentials", LFPs, represent the activity of the collection of neurons surrounding the tip of the electrode, and will be measured during surgery along the path used for the placement of the DBS electrode. The goal of this project is to determine whether this additional data from surrounding neurons will help with optimal placement of the DBS electrode.

NCT ID: NCT02067702 Completed - Essential Tremor Clinical Trials

Limb Cooling in Essential Tremor

Start date: October 2014
Phase:
Study type: Observational

Essential Tremor (ET) is characterized by tremors affecting the arms. The investigators will examine the effects of non-pharmacological limb cooling on clinical and physiological characteristics in patients presenting with ET at three different temperatures; and will measure changes in tremor amplitude after cooling of the upper limb.

NCT ID: NCT02052271 Completed - Essential Tremor Clinical Trials

Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation

ELECTRE2
Start date: June 3, 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether transcranial cathodal direct current stimulation (tDCS) delivered over the cerebellum can improve essential tremor.

NCT ID: NCT02046863 Completed - Parkinson's Disease Clinical Trials

Pilot Study for Automated Deep Brain Stimulation Programming

Start date: November 2013
Phase: N/A
Study type: Interventional

The clinical utility of deep brain stimulation (DBS) for the treatment of movement disorders such as Parkinson's disease has been well established; however, there is a great disparity in outcomes among DBS recipients due to varied postoperative management, particularly concerning the choosing of an optimal set of programming parameters from the thousands of possible combinations. This study will evaluate the use of motion sensor based assessments to develop a functional map and algorithms to automatically determine a set of programming parameters that maximize symptomatic benefits while minimizing side effects and battery consumption.